PRIA Logo™
119-s-2062119th CongressWALLET

RAPID Reserve Act

Sponsored By: Senator Peters, Gary C. [D-MI]

Introduced

Summary

This bill would create a rolling reserve program to build six‑month domestic reserves of critical drugs and their active pharmaceutical ingredients (APIs) to shore up vulnerable supply chains and prevent shortages during emergencies. It authorizes contracts and awards to eligible manufacturers and partners to hold, replenish, and, when needed, transfer those reserves under HHS direction.

Show full summary
  • Manufacturers and distributors would have to maintain a six‑month reserve of APIs and finished drug products at registered domestic or OECD facilities and replenish those stocks with recently manufactured material. They must also agree to produce drugs or transfer API to other makers if supply gaps arise.
  • Patients and health systems would gain a steadier supply of drugs judged critical for public health emergencies or at‑risk populations, reducing the chance that shortages interrupt care. The bill targets drugs with “vulnerable supply chains.”
  • Federal preparedness and domestic manufacturing would get new tools. HHS must publish the list of covered drugs, issue guidance within 180 days, prefer domestic sourcing when awarding contracts, and may fund construction or renovation to boost surge capacity.

*If enacted, it would authorize $500 million for FY2026 to carry out the program, increasing federal spending.*

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

Backup supply of critical medicines

This bill would create a national rolling reserve program at HHS for critical drugs and their active ingredients. HHS would award contracts to companies to make, test, store, and ship these drugs. Awarded companies would need to hold about a six-month supply of APIs and finished product in U.S. or OECD facilities. They would have to keep supplies recently made and replenish them. HHS could direct production, order transfers of API to other makers, and allocate reserves in emergencies. HHS must publish the list of covered drugs and issue guidance within 180 days. HHS would report to Congress two years after the first award and every two years after. The bill would authorize $500 million for fiscal year 2026 to carry out the program. This authorization would set a ceiling but would not actually provide the money.

Sponsors & CoSponsors

Sponsor

Peters, Gary C. [D-MI]

MI • D

Cosponsors

  • Sen. Blackburn, Marsha [R-TN]

    TN • R

    Sponsored 6/12/2025

  • Sen. Budd, Ted [R-NC]

    NC • R

    Sponsored 6/12/2025

  • Sen. Kaine, Tim [D-VA]

    VA • D

    Sponsored 6/12/2025

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation